National Institute of Allergy & Infectious Diseases (NIAID)
31 Center Drive MSC 2520
Building 31, Room 7A-50
Bethesda
Maryland
20892-2520
United States
Tel: 301-496-5717
Website: http://www.niaid.nih.gov/
294 articles with National Institute of Allergy & Infectious Diseases (NIAID)
-
Adjuvance Technologies Announces NIH Funding for COVID-19 Vaccine Research
5/19/2020
Adjuvance Technologies announced today that it has been awarded supplemental contract funding from The National Institute of Allergy and Infectious Diseases (NIAID). The funds will be used to evaluate TQL1055, manufactured by Adjuvance, with SARS-CoV2 antigen, manufactured by NIH (National Institutes of Health). TQL1055 is Adjuvance’s novel Saponin vaccine adjuvant. The total funding in this contract is $1.47million. “
-
In an interview with National Geographic, Fauci once again sided with the evidence that indicates the virus is a species jumper and originated in the animal kingdom.
-
“Although a 31% improvement doesn’t seem like a knockout 100%, it is a very important proof of concept,” said Anthony S. Fauci, director of NIAID. “What it has proven is that a drug can block this virus. This will be the standard of care.”
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
-
Integral Molecular Receives NIAID Award to Combat COVID-19
4/23/2020
The National Institute of Allergy and Infectious Diseases has awarded Integral Molecular $1 million to enable the application of Integral Molecular's technology platforms to aid in the discovery of vaccines and therapeutics to combat COVID-19.
-
On March 16, Moderna and the National Institute of Allergy and Infectious Disease (NIAID) began dosing patients with mRNA-1273, its vaccine candidate against COVID-19. The second round of dosing in healthy Seattle volunteers has now begun.
-
BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19
4/9/2020
BioCryst Pharmaceuticals, Inc. announced that the company has opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19.
-
Novel Coronavirus Can Survive in Aerosol Form and on Hard Surfaces for Hours to Days, Study Reveals
3/18/2020
As the world shifts toward a concept of social distancing as part of an attempt to protect against the novel coronavirus, new research is showing the virus that causes COVID-19 is quite stable on hard surfaces, and even in the air. -
OyaGen, Inc. Announces a Compound in Development with Broad Antiviral Activity Against Coronaviruses, including SARS-CoV-2
3/11/2020
OyaGen, Inc. announced today new unpublished results from collaborative research with the National Institute of Allergy and Infectious Diseases' Integrated Research Facility at Fort Detrick, MD
-
Clinical Catch-Up: February 3-7, 2020
2/10/2020
Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look. -
The National Institutes of Health ceased administration of an investigational HIV vaccine after interim data revealed that the treatment was not working in preventing the virus.
-
HIV Vaccine Trial HVTN 702 Stopped Early for Non-Efficacy; Other Vaccine Trials Not Affected; AVAC Calls for Ongoing Support to Vaccine Research
2/3/2020
NEW YORK , Feb. 3, 2020 /PRNewswire/ -- Today the US National Institute of Allergy and Infectious Diseases (NIAID) announced that HVTN 702, a large-scale HIV vaccine efficacy trial of a canary pox-based vaccine candidate, has been stopped vaccinations because the vaccine does not prevent HIV.
-
Emmes Will Support Development of a New Universal Flu Vaccine for The National Institute of Allergy and Infectious Diseases
12/2/2019
The Company's Contract with Digital Infuzion Adds New Dimension to its Long NIAID History
-
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention
11/21/2019
Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells.
-
IDT Biologika Awarded New Task Order in the Scope of 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases
11/5/2019
IDT Biologika announced that the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, an agency of the United States Department of Health and Human Services, has awarded the company a new Task Order within the 10-year Indefinite Delivery, Indefinite Quantity contract no. HHSN272201800011I to provide process development activities and production of a vaccine against the Respiratory Syncytial Virus.
-
BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine
10/23/2019
The Phase 1 clinical study is expected to begin enrollment this year and is being funded by the National Institute of Allergy and Infectious Diseases, an institute within the National Institutes of Health
-
PBL gains approval to advance next generation anthrax vaccine to Phase 1 clinical trial
10/22/2019
Porton Biopharma Ltd has announced that it has signed a modification to its contract with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases to advance a next generation intra-nasal anthrax vaccine into the clinical-trial phase.
-
Tesamorelin Study Results on NAFLD Published in Lancet HIV
10/11/2019
Theratechnologies Inc. is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease in HIV were published in the Lancet HIV.
-
Versatope Awarded up to $17.9M for a Universal Influenza Vaccine
9/25/2019
The award is through the Broad Agency Announcement (BAA) program to advance Versatope's universal influenza vaccine candidate.
-
Progentec Diagnostics Awarded SBIR Fast-Track Grant to Develop Immune Mediator-Based Blood Tests for Clinical Disease Activity in Lupus (SLE)
7/26/2019
In-development laboratory tests will inform concurrent and future clinical disease activity